equecabtagene autoleucel
AXP000021.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- TNFRSF17
- Originator
- IASO Biotherapeutics
- Sponsor
- IASO Biotherapeutics
Names
| Name | Type | Source |
|---|---|---|
| equecabtagene autoleucel | preferred name, INN | curator, ncit |
| Fucaso | brand | press |
| CT103A | code | ncit |
| IBI326 | code | press |
| eque-cel | synonym | press |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- lentivirus
- Replication
- non replicating
- Modifications
- lentiviral vector carrying a CAR with a fully human scFv against BCMA, a CD8 alpha hinge and transmembrane region, a 4-1BB costimulatory domain and a CD3 zeta activation domain
- Transgenes
- anti-BCMA chimeric antigen receptor
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C185123
- FDA UNII
- YTJ3XRJ4ZN
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| NMPA | CN | 2023-07 | approved | Fucaso | Adults with relapsed or refractory multiple myeloma after three or more prior lines including at least one proteasome inhibitor and an immunomodulatory agent | source |
Clinical trials (12)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07752264 | A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy | Not yet recruiting | Phase 1/2 | 2026-08-15 | 2030-08-15 | 27 | Refractory Immune-mediated Necrotizing Myopathy |
| NCT07510100 | Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | Not yet recruiting | Phase 1/2 | 2026-05-10 | 2029-08-31 | 17 | Relapsed/Refractory Multiple Myeloma |
| NCT07055724 | Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis | Not yet recruiting | Phase 2 | 2025-07 | 2027-06 | 17 | AL Amyloidosis |
| NCT06902844 | Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE) | Recruiting | 2025-04-05 | 2027-10-31 | 6 | Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE) | |
| NCT07028970 | Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection | Recruiting | 2024-12-15 | 2040-12 | 1500 | Multiple Myeloma | |
| NCT06369935 | A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. | Not yet recruiting | 2024-06-20 | 2026-08-20 | 260 | Relapsed/Refractory Multiple Myeloma | |
| NCT06464991 | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) | Active not recruiting | Phase 3 | 2024-03-27 | 2027-08 | 260 | Multiple Myeloma |
| NCT05698303 | A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | Unknown | Phase 1 | 2023-05-08 | 2024-05-20 | 12 | Multiple Myeloma |
| NCT05181501 | A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) | Not yet recruiting | Phase 1 | 2022-04 | 2024-04 | 20 | Multiple Myeloma |
| NCT05201118 | A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma | Unknown | Phase 1 | 2022-01-01 | 2022-12-31 | 20 | Extramedullary Multiple Myeloma |
| NCT04561557 | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | Recruiting | Early phase 1 | 2020-09-22 | 2027-02-22 | 36 | Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Autoimmune Encephalitis; Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Idiopathic Inflammatory Myopathies; Multiple Sclerosis; Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD); Neuromyelitis Optica Spectrum Disorder; POEMS Syndrome |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) | Unknown | Phase 1/2 | 2020-04-01 | 2022-10 | 132 | Multiple Myeloma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42775240 | Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chimeric antigen receptor T-cell immunotherapy in an advanced disease stage: A case report. | Experimental and therapeutic medicine | 2026 | name in abstract: equecabtagene autoleucel |
| PMID 42845783 | Equecabtagene autoleucel as sequential therapy in a multiple myeloma patient with renal failure: a case report. | Frontiers in medicine | 2026 | name in title: equecabtagene autoleucel |
| PMID 42867544 | BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case report. | Annals of hematology | 2026 | name in abstract: equecabtagene autoleucel |
| PMID 40308587 | First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report. | Frontiers in immunology | 2025 | name in abstract: equecabtagene autoleucel |
| PMID 40380297 | Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. | Journal of translational medicine | 2025 | name in abstract: equecabtagene autoleucel |
| PMID 40425008 | Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy. | Med (New York, N.Y.) | 2025 | cited by trial NCT04561557 |
| PMID 41101309 | Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. | Cell | 2025 | cited by trial NCT04561557 |
| PMID 36596762 | Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. | Signal transduction and targeted therapy | 2023 | name in title: CT103A |
| PMID 37192741 | Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. | British journal of haematology | 2023 | cited by trial NCT05066646 |
| PMID 37658205 | Equecabtagene Autoleucel: First Approval. | Molecular diagnosis & therapy | 2023 | cited by trial NCT04561557 |
| PMID 36137648 | Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report. | Journal for immunotherapy of cancer | 2022 | name in abstract: CT103A |
| PMID 33512480 | A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. | Blood | 2021 | name in title: CT103A |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41428622 | 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turkish journal of haematology : official journal of Turkish Society of Haematology | 2026 | name in abstract: eque-cel |
| PMID 41721717 | Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma. | Hematological oncology | 2026 | name in abstract: equecabtagene autoleucel |
| PMID 39520053 | Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in title: CT103A |
| PMID 41176941 | CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation. | Multiple sclerosis and related disorders | 2025 | name in abstract: CT103A |
| PMID 41439964 | Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma. | Cells | 2025 | name in abstract: CT103A |
| PMID 38821074 | Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. | The Lancet. Oncology | 2024 | name in abstract: equecabtagene autoleucel |
| PMID 39509090 | Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial. | JAMA oncology | 2024 | name in title: equecabtagene autoleucel |
| PMID 37964302 | A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma. | Journal of translational medicine | 2023 | name in abstract: CT103A |
| PMID 35185564 | A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy. | Frontiers in pharmacology | 2022 | name in title: CT103A |
| PMID 35402835 | CT103A, a forward step in multiple myeloma immunotherapies. | Blood science (Baltimore, Md.) | 2021 | name in title: CT103A |
Notes
Fully human anti-BCMA scFv CAR; co-developed by IASO Bio and Innovent (IBI326). Approved in China 2023.
How to cite
equecabtagene autoleucel (AXP000021.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000021.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.